Alvista Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-06-2024
- Paid Up Capital ₹ 0.10 M
as on 15-06-2024
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.34 M
as on 15-06-2024
- Revenue -34.75%
(FY 2023)
- Profit 25.54%
(FY 2023)
- Ebitda 78.54%
(FY 2023)
- Net Worth 8.65%
(FY 2023)
- Total Assets 23.36%
(FY 2023)
About Alvista Biosciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.34 M.
Rajat Tuteja, Kamlesh Tuteja, Dinesh Juneja, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304DL2018PTC330995
- Company No.
330995
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Mar 2018
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Alvista Biosciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajat Tuteja  | Director | 15-Mar-2018 | Current |
| Kamlesh Tuteja | Director | 15-Mar-2018 | Current |
| Dinesh Juneja | Director | 15-Mar-2018 | Current |
| Mukesh Juneja | Director | 15-Mar-2018 | Current |
Financial Performance of Alvista Biosciences.
Alvista Biosciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 34.75% decrease. The company also saw a substantial improvement in profitability, with a 25.54% increase in profit. The company's net worth moved up by a moderate rise of 8.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alvista Biosciences?
In 2023, Alvista Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Qcure Biosciences Private LimitedActive 3 years 3 monthsRajat Tuteja, Dinesh Juneja and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Apr 2022 | ₹1.16 M | Open |
Hdfc Bank Limited Creation Date: 26 Nov 2021 | ₹2.10 M | Open |
Hdfc Bank Limited Creation Date: 15 Apr 2021 | ₹2.08 M | Open |
How Many Employees Work at Alvista Biosciences?
Unlock and access historical data on people associated with Alvista Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alvista Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alvista Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
